Shopping Cart 0
Cart Subtotal
AED 0

Grunenthal GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company. It researches, develops, produces and markets products for the treatment of pain and innovative formulations of established active substances. The company provides new chemical entities including opioids for moderate to severe pain, vanilloid receptors and KCNQ channel openers for chronic neuropathic pain; and the Bradykinin receptor for the treatment of chronic diseases with inflammation. Grunenthal also focuses on discovering new methods to treat pain, developing new medical devices, and new platform technologies for drug delivery. The company operates along with its subsidiaries in Europe, Latin America and the US. Grunenthal is headquartered in Aachen, Germany.

Grunenthal GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 15

Grunenthal Acquires Rights to Zomic from AstraZeneca 16

Grunenthal to Acquire Qutenza from Astellas Pharma Europe 17

Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 18

Venture Financing 19

Thar Pharma Raises USD0.12 Million in Venture Financing 19

Thar Pharma Raises Additional USD2 Million in Venture Financing 20

Thar Pharma Raises Additional USD1.54 Million in Venture Financing 21

Thar Pharma Raises Additional USD 0.08 Million In Venture Financing 22

Partnerships 23

Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 23

Grunenthal and KU Leuven Enter into Research Agreement 25

Grunenthal Enters into Distribution Agreement with Merck 26

Helsinn and Grunenthal Enter into Agreement for Akynzeo 27

Grunenthal Enters into Agreement with Axxam 28

Patheon Enters into Co-Development Agreement with Grunenthal 29

Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 30

Thar Pharma Enters into Co-Development Agreement 31

Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 32

Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 33

Grunenthal Enters into Agreement with Proteus and Boston Children's Hospital 34

Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 35

AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 36

Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 38

Licensing Agreements 39

Grunenthal to Receive Rights for Nexium from AstraZeneca 39

Grunenthal to Receive Rights for Vimovo from AstraZeneca 40

Mundipharma Enters into Licensing Agreement with Grunenthal 41

Grunenthal Enters into Licensing Agreement with AstraZeneca 42

Mundipharma Enters Into Licensing Agreement With Grunenthal 43

Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 44

Grunenthal Enters into Licensing Agreement with Abiogen Pharma 45

Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 46

Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 47

BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 48

Equity Offering 49

Thar Pharma Postpones IPO for USD50 Million 49

Asset Transactions 50

Depomed Acquires Rights of Cebranopadol from Grunenthal 50

STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For USD 230 Million 52

Acquisition 54

Grunenthal Acquires Thar Pharma 54

Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 55

Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 56

Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 57

Grunenthal GmbH-Key Competitors 58

Grunenthal GmbH-Key Employees 59

Grunenthal GmbH-Locations And Subsidiaries 60

Head Office 60

Other Locations & Subsidiaries 60

Recent Developments 63

Strategy And Business Planning 63

Oct 31, 2018: AstraZeneca signs USD 922m licensing deal with Grunenthal 63

May 10, 2017: Grunenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward 64

Corporate Communications 65

Sep 01, 2017: Mark Fladrich Takes office as the New CCO of the Grunenthal Group 65

May 09, 2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal 66

Government and Public Interest 67

Nov 16, 2017: Research Consortium led by Grunenthal receives EUR 2 million grant from the European Fund for Regional Development and the State of North Rhine-Westphalia 67

May 23, 2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives-EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects 68

Product News 69

Jul 07, 2017: Grunenthal Group: Launch of the Project-Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET) 69

Appendix 70

Methodology 70

About GlobalData 70

Contact Us 70

Disclaimer 70


List Of Figure

List of Figures

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Grunenthal GmbH, Pharmaceuticals & Healthcare, Key Facts 2

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Grunenthal GmbH, Deals By Therapy Area, 2012 to YTD 2018 10

Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 15

Grunenthal Acquires Rights to Zomic from AstraZeneca 16

Grunenthal to Acquire Qutenza from Astellas Pharma Europe 17

Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 18

Thar Pharma Raises USD0.12 Million in Venture Financing 19

Thar Pharma Raises Additional USD2 Million in Venture Financing 20

Thar Pharma Raises Additional USD1.54 Million in Venture Financing 21

Thar Pharma Raises Additional USD 0.08 Million In Venture Financing 22

Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 23

Grunenthal and KU Leuven Enter into Research Agreement 25

Grunenthal Enters into Distribution Agreement with Merck 26

Helsinn and Grunenthal Enter into Agreement for Akynzeo 27

Grunenthal Enters into Agreement with Axxam 28

Patheon Enters into Co-Development Agreement with Grunenthal 29

Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 30

Thar Pharma Enters into Co-Development Agreement 31

Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 32

Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 33

Grunenthal Enters into Agreement with Proteus and Boston Children's Hospital 34

Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 35

AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 36

Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 38

Grunenthal to Receive Rights for Nexium from AstraZeneca 39

Grunenthal to Receive Rights for Vimovo from AstraZeneca 40

Mundipharma Enters into Licensing Agreement with Grunenthal 41

Grunenthal Enters into Licensing Agreement with AstraZeneca 42

Mundipharma Enters Into Licensing Agreement With Grunenthal 43

Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 44

Grunenthal Enters into Licensing Agreement with Abiogen Pharma 45

Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 46

Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 47

BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 48

Thar Pharma Postpones IPO for USD50 Million 49

Depomed Acquires Rights of Cebranopadol from Grunenthal 50

STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For USD 230 Million 52

Grunenthal Acquires Thar Pharma 54

Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 55

Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 56

Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 57

Grunenthal GmbH, Key Competitors 58

Grunenthal GmbH, Key Employees 59

Grunenthal GmbH, Other Locations 60

Grunenthal GmbH, Subsidiaries 60

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company. It researches, develops, produces and markets products for the treatment of pain and innovative formulations of established active substances. The company provides new chemical entities including opioids for moderate to severe pain, vanilloid receptors and KCNQ channel openers for chronic neuropathic pain; and the Bradykinin receptor for the treatment of chronic diseases with inflammation. Grunenthal also focuses on discovering new methods to treat pain, developing new medical devices, and new platform technologies for drug delivery. The company operates along with its subsidiaries in Europe, Latin America and the US. Grunenthal is headquartered in Aachen, Germany.

Grunenthal GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 15

Grunenthal Acquires Rights to Zomic from AstraZeneca 16

Grunenthal to Acquire Qutenza from Astellas Pharma Europe 17

Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 18

Venture Financing 19

Thar Pharma Raises USD0.12 Million in Venture Financing 19

Thar Pharma Raises Additional USD2 Million in Venture Financing 20

Thar Pharma Raises Additional USD1.54 Million in Venture Financing 21

Thar Pharma Raises Additional USD 0.08 Million In Venture Financing 22

Partnerships 23

Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 23

Grunenthal and KU Leuven Enter into Research Agreement 25

Grunenthal Enters into Distribution Agreement with Merck 26

Helsinn and Grunenthal Enter into Agreement for Akynzeo 27

Grunenthal Enters into Agreement with Axxam 28

Patheon Enters into Co-Development Agreement with Grunenthal 29

Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 30

Thar Pharma Enters into Co-Development Agreement 31

Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 32

Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 33

Grunenthal Enters into Agreement with Proteus and Boston Children's Hospital 34

Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 35

AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 36

Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 38

Licensing Agreements 39

Grunenthal to Receive Rights for Nexium from AstraZeneca 39

Grunenthal to Receive Rights for Vimovo from AstraZeneca 40

Mundipharma Enters into Licensing Agreement with Grunenthal 41

Grunenthal Enters into Licensing Agreement with AstraZeneca 42

Mundipharma Enters Into Licensing Agreement With Grunenthal 43

Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 44

Grunenthal Enters into Licensing Agreement with Abiogen Pharma 45

Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 46

Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 47

BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 48

Equity Offering 49

Thar Pharma Postpones IPO for USD50 Million 49

Asset Transactions 50

Depomed Acquires Rights of Cebranopadol from Grunenthal 50

STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For USD 230 Million 52

Acquisition 54

Grunenthal Acquires Thar Pharma 54

Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 55

Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 56

Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 57

Grunenthal GmbH-Key Competitors 58

Grunenthal GmbH-Key Employees 59

Grunenthal GmbH-Locations And Subsidiaries 60

Head Office 60

Other Locations & Subsidiaries 60

Recent Developments 63

Strategy And Business Planning 63

Oct 31, 2018: AstraZeneca signs USD 922m licensing deal with Grunenthal 63

May 10, 2017: Grunenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward 64

Corporate Communications 65

Sep 01, 2017: Mark Fladrich Takes office as the New CCO of the Grunenthal Group 65

May 09, 2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal 66

Government and Public Interest 67

Nov 16, 2017: Research Consortium led by Grunenthal receives EUR 2 million grant from the European Fund for Regional Development and the State of North Rhine-Westphalia 67

May 23, 2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives-EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects 68

Product News 69

Jul 07, 2017: Grunenthal Group: Launch of the Project-Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET) 69

Appendix 70

Methodology 70

About GlobalData 70

Contact Us 70

Disclaimer 70


List Of Figure

List of Figures

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Grunenthal GmbH, Pharmaceuticals & Healthcare, Key Facts 2

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Grunenthal GmbH, Deals By Therapy Area, 2012 to YTD 2018 10

Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 15

Grunenthal Acquires Rights to Zomic from AstraZeneca 16

Grunenthal to Acquire Qutenza from Astellas Pharma Europe 17

Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 18

Thar Pharma Raises USD0.12 Million in Venture Financing 19

Thar Pharma Raises Additional USD2 Million in Venture Financing 20

Thar Pharma Raises Additional USD1.54 Million in Venture Financing 21

Thar Pharma Raises Additional USD 0.08 Million In Venture Financing 22

Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 23

Grunenthal and KU Leuven Enter into Research Agreement 25

Grunenthal Enters into Distribution Agreement with Merck 26

Helsinn and Grunenthal Enter into Agreement for Akynzeo 27

Grunenthal Enters into Agreement with Axxam 28

Patheon Enters into Co-Development Agreement with Grunenthal 29

Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 30

Thar Pharma Enters into Co-Development Agreement 31

Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 32

Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 33

Grunenthal Enters into Agreement with Proteus and Boston Children's Hospital 34

Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 35

AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 36

Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 38

Grunenthal to Receive Rights for Nexium from AstraZeneca 39

Grunenthal to Receive Rights for Vimovo from AstraZeneca 40

Mundipharma Enters into Licensing Agreement with Grunenthal 41

Grunenthal Enters into Licensing Agreement with AstraZeneca 42

Mundipharma Enters Into Licensing Agreement With Grunenthal 43

Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 44

Grunenthal Enters into Licensing Agreement with Abiogen Pharma 45

Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 46

Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 47

BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 48

Thar Pharma Postpones IPO for USD50 Million 49

Depomed Acquires Rights of Cebranopadol from Grunenthal 50

STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For USD 230 Million 52

Grunenthal Acquires Thar Pharma 54

Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 55

Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 56

Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 57

Grunenthal GmbH, Key Competitors 58

Grunenthal GmbH, Key Employees 59

Grunenthal GmbH, Other Locations 60

Grunenthal GmbH, Subsidiaries 60

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS